#	Pagina
attuale pagina	/open-h2020/projects/197029/index.html
-1	/open-h2020/per-topic/haystack/list/index.html
-2	/open-h2020/per-topic/calc/list/index.html
-3	/open-h2020/per-topic/leoben/list/index.html
-4	/open-h2020/per-topic/checking/list/index.html
-5	/open-h2020/per-topic/highlighted/list/index.html
-6	/open-h2020/per-topic/tcsab/list/index.html
-7	/open-h2020/per-topic/solarbox/list/index.html

Opendata, web and dolomites

HTMD

Feasibility assessment of a cloud application platform for rational drug design using high throughput molecular dynamics

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

HTMD project word cloud

Explore the words cloud of the HTMD project. It provides you a very rough idea of what is the project "HTMD" about.

description computationally inform solution unprecedented uniquely entry prototyping subsequent progress beginning pace spending productivity instrument industry acellera accurate interact speed preparations traction interactions disruptive candidate virtualizing gain global demonstration interfaces accuracy looks silico larger combines simulations approved feasibility significantly htmd proprietary resource biological environment barrier positioned dynamics degree competitiveness limits companies throughput drug viability launch provides trl rational pharmaceutical unnecessary workflows pcr clinical translating computational drugs proposing reduce invest 1000m identification simulation cloud optimized md ready proposes sme market approximately leader platform resolution discovery substantially complexity expensive molecular

Project "HTMD" data sheet

The following table provides information about the project.

Coordinator	ACELLERA LABS SL Organization address address: C/ DELS PINZON 19 2-4 city: BARCELONA postcode: 8003 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
Code Call	H2020-SMEINST-1-2014
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-06-01 to 2015-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ACELLERA LABS SL ACELLERA LABS SL Organization address address: C/ DELS PINZON 19 2-4 city: BARCELONA postcode: 8003 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	coordinator	50˙000.00

Map

Project objective

The pharmaceutical industry’s increasing spending on R&D is not translating into new and better drugs at the pace required to maintain competitiveness. In-silico computational methods are beginning to gain traction in the progress towards more rational drug discovery workflows. Among the methods available, molecular dynamics (MD) provides the most accurate and useful description of molecular interactions, but the current state of the art has both a high degree of unnecessary technical complexity, and is computationally expensive. Together, these two factors have produced a high barrier to entry that substantially limits research productivity.Acellera looks to address these issues by proposing a cloud application platform for high-throughput MD (HTMD) simulations. This computational platform combines proprietary simulation technology - optimized for speed and simulation throughput – and user-friendly interfaces in a cloud environment to provide a novel resource for drug candidate identification. HTMD, which allows understanding with an unprecedented degree of resolution and accuracy how drugs interact with their biological targets, can significantly reduce the cost of pre-clinical research (PCR) by virtualizing key steps. It is currently estimated that pharmaceutical companies invest approximately 1000M Euro per approved drug. As a global leader in the development of technology for high-throughput molecular dynamics, Acellera is uniquely positioned to bring this disruptive computational technology to the market. The HTMD platform is ready for prototyping in an operational environment (TRL 6). Acellera proposes a Phase 1 SME Instrument to support the execution of a feasibility study into the market viability of the HTMD solution for pre-clinical research. Results of the study will be used to inform preparations for a larger-scale demonstration in Phase 2 and for the subsequent market launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HTMD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HTMD" are provided by the European Opendata Portal: CORDIS opendata.